samedan logo
 
 
 
spacer
home > ebr > summer 2003 > mass-based fraction collection of crude synthetic peptides in analytical and preparative scale for cancer treatment
PUBLICATIONS
European Biopharmaceutical Review

Mass-Based Fraction Collection of Crude Synthetic Peptides in Analytical and Preparative Scale for cancer treatment

Synthetic peptides become more and more important as drug candidates in the treatment of a variety of diseases. A particular therapeutic focus for synthetic peptides is cancer treatment (1, 2). In order to keep pace with the growing number of newly synthesised peptides, peptide purification should not represent a bottleneck in the drug discovery process. Since the target masses of synthetic peptides are well known, mass-based fraction collection represents an efficient technique for their purification. In contrast to fraction triggering with less specific detectors, employing a mass selective detector only leads to the purification of the target mass in each run. Consequently, it is not necessary to pick out the compound of interest from a series of redundant fractions.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Ralf Moritz, Application Chemist at Agilent Technologies, and Nicola O'Reilly at Cancer Research UK
Ralf Moritz studied Chemistry at Gerhard Mercator University, Germany, before moving to McMaster University in Canada for a year in 1993.

He completed his PhD thesis at Robert Koch-Institute, Berlin in 2000 before undertaking research work at the Max Delbrück Centrum for Molecular Medicine, Berlin. Since 2001 Ralf has been an Application Chemist at Agilent Technologies, Germany.


Nicola O'Reilly received a BSc (Hons) in Chemistry from Southampton University in 1987. She then joined Cancer Research UK (then Imperial Cancer Research Fund), running the peptide synthesis laboratory.

In 1994 Nicola completed a master's degree in Biochemistry at King's College London. In October 1999 she set up a new 2D gel electrophoresis facility and in July 2000 she took over the ICRF Protein Isolation Service. After the formation of Cancer Research UK she opened up peptide synthesis and protein isolation to new Cancer Research UK clients.


spacer
Ralf Moritz
spacer
spacer
spacer
Nicola O'Reilly
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Team Consulting expands facilities to meet client demand

To meet growing client demand, Team Consulting, a medical device design and development consultancy based in Ickleton, Cambridge, has expanded its facilities to now offer over 5,500 sq ft of lab spaces. Based in the picturesque 13th century Abbey Barns site, the company’s expansion sees the addition of a whole new building with several high-spec lab spaces, design facilities and collaborative workspaces.
More info >>

White Papers

Crunch Time: The Impact of Serialisation Requirements on Packaging Operations

PCI Pharma Services

The deadlines for including unique product identifiers on prescription drugs is putting a strain on multiple parts of the industry, much of which is ill-prepared to meet the target. Here, we look to the experience of a company that is ahead of the curve for lessons on how to manage and ease the transition to serialisation.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement